About Artiva Biotherapeutics
Artiva Biotherapeutics is a clinical-stage biotechnology company that develops off-the-shelf, allogeneic natural killer (NK) cell therapies for patients with autoimmune diseases and cancers. Its lead program, AlloNK® (AB-101), is a non-genetically modified NK cell therapy candidate in clinical trials for conditions including lupus nephritis and Non-Hodgkin Lymphoma. Founded in 2019 as a spin-out of GC Cell (South Korea), Artiva holds exclusive worldwide rights (excluding Asia, Australia, and New Zealand) to GC Cell's NK cell manufacturing technology.
Company details
Funding
Total raised
$498M
Last stage
Public
Investors
Founders
Tom Farrell
Co-founder of Artiva Biotherapeutics, listed on Crunchbase as one of the two founders of the company.
LinkedInFred Aslan
Joined Artiva as CEO in January 2021 and led the Series B financing and IPO. Previously President and CBO at Vividion Therapeutics (acquired by Bayer) and had a 12-year affiliation with Venrock.
Peter Flynn
Co-founder of Artiva Biotherapeutics with 22+ years of biotech experience. Former EVP at Orexigen Therapeutics and SVP of Early Program Development at Fate Therapeutics. Holds a PhD in Molecular Biology from UCL.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.